Webinars
PathoQuest in BioPharma Asia webinar: CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy
🧬Advanced gene therapy development programs require innovative paths to reach licensure promptly ⏱
This Thursday 23rd March 2022 | 10:00am EST / 2:00pm GMT / 3:00pm CET | learn more on those applications and how #NGS fits into it with @biopharma Asia webinar 💻presented by @Sarah Thomas, from @REGENXBIO Inc. and followed by @Joanna Zmurko from @pathoquest
CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy
PathoQuest in AdeBiotech’s webinar on high throughput sequencing applications – 2nd edition (in French)
Sébastien Renouf is presenting “NGS-Based QC Solutions at GMP Grade: Derisking Biomanufacturing Processes and Reducing Time to Market”
– French speaking webinar –
PathoQuest in BioPharma Asia webinar: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) BASED METHODS FOR DETECTION OF VIRAL CONTAMINANTS IN BIOMANUFACTURING
Contamination of a biological product with viruses, potentially harmful for humans, is of concern for therapeutics derived from human and animal sources.
To learn more on NGS 🧬 based fast and safer biosafety solutions, with Jurgen Mullberg Bristol Myers Squibb and Joanna Zmurko PathoQuest
Exclusive study “Use of NGS to replace animal tests for the viral safety of biologics”
The industry needs to bring safer biologics to patient in a more ethical and time effective. Classical viral safety testing approaches often fail to keep pace with the demands faced with new and innovative biomedicines and they have fallen out of favor considering the 3Rs (replacement, reduction, refinement of animal testing). See the calendar in regards with the presentation of the new comparison study between NGS and in vivo.
PathoQuest in BioPharma Asia webinar: VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS
VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologics. Adventitious agents (viruses, bacteria, mycoplasma,…
Watch the replay of our webinar – Accelerated vaccines development and production: in-process NGS QC testing for risk mitigations
Archived version of our webinar: Accelerated vaccines development and production: in-process NGS QC testing for risk mitigations Appropriate safety testing is an important part of vaccine development and production.
Pick another category:
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.
Connect
